Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oasmia Pharmaceutical AB (publ)
  6. Summary
    OASM   SE0000722365

OASMIA PHARMACEUTICAL AB (PUBL)

(OASM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
2.17(c) 2.268(c) 2.268(c) 2.371(c) 2.26(c) Last
567 597 1 306 191 795 609 7 757 687 2 217 133 Volume
-0.41% +4.52% 0.00% +4.54% -4.68% Change
More quotes
Estimated financial data (e)
Sales 2021 10,2 M 1,19 M 1,19 M
Net income 2021 -173 M -20,1 M -20,1 M
Net cash position 2021 130 M 15,2 M 15,2 M
P/E ratio 2021 -5,65x
Yield 2021 -
Sales 2022 40,2 M 4,69 M 4,69 M
Net income 2022 -144 M -16,8 M -16,8 M
Net cash position 2022 3,04 M 0,36 M 0,36 M
P/E ratio 2022 -7,17x
Yield 2022 -
Capitalization 1 013 M 118 M 118 M
EV / Sales 2021 86,6x
EV / Sales 2022 25,1x
Nbr of Employees 25
Free-Float 61,3%
More Financials
Company
Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of drugs in diseases such as cancer. Product development is based on Oasmia’s drug delivery platform which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that usually require chemical solubilizers for... 
Sector
Pharmaceuticals
Calendar
11/18Earnings Release
More about the company
All news about OASMIA PHARMACEUTICAL AB (PUBL)
10/21OASMIA PHARMACEUTICAL : announces global settlement of all disputes with MGC Capital, form..
AQ
10/20OASMIA PHARMACEUTICAL : Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutic..
AQ
10/08OASMIA PHARMACEUTICAL (OASM) : Focused on pillars of growth
DJ
10/01OASMIA PHARMACEUTICAL : Naventus LifeScience Summit
PU
09/24OASMIA PHARMACEUTICAL : to present at Naventus Life Science Summit on September 29
AQ
09/20OASMIA PHARMACEUTICAL : Notice of Extraordinary General Meeting in Oasmia Pharmaceutical A..
AQ
09/17OASMIA PHARMACEUTICAL : signs agreement with FarmaMondo to commercialize Paclical® in Russ..
AQ
09/17Oasmia Pharmaceutical AB Signs Agreement with FarmaMondo to Commercialize Paclical® in ..
CI
09/07OASMIA PHARMACEUTICAL : Presentation på Aktiedagen Stockholm
PU
08/31OASMIA PHARMACEUTICAL : to present at Aktiedagen Stockholm on September 7
AQ
08/26OASMIA PHARMACEUTICAL : strengthens internal capabilities with the appointments of Head of..
AQ
08/26Oasmia Pharmaceutical AB Announces Executive Appointments
CI
08/19OASMIA PHARMACEUTICAL : Interim report for the period January 1, 2021 – June 30, 202..
PU
08/19Oasmia Pharmaceutical AB Publ Reports Earnings Results for the Second Quarter Ended Jun..
CI
08/11OASMIA PHARMACEUTICAL : First Patient enrolled in the SAKK Investigator-Initiated Phase 1b..
AQ
More news
News in other languages on OASMIA PHARMACEUTICAL AB (PUBL)
2020OASMIA PHARMACEUTICAL AB (PUBL) : un partenariat stratégique pour la distribution d'Apeale..
2020OASMIA PHARMACEUTICAL AB (PUBL) : Apealea arrive sur les marchés scandinaves
More news
Chart OASMIA PHARMACEUTICAL AB (PUBL)
Duration : Period :
Oasmia Pharmaceutical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OASMIA PHARMACEUTICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,26 SEK
Average target price 5,70 SEK
Spread / Average Target 152%
EPS Revisions
Managers and Directors
François R. Martelet Chief Executive Officer
Fredrik Järrsten Chief Financial Officer
Karl Anders Olof Härfstrand Chairman
Mikael Asp Chief Technology Officer
Carina Eklöw Director-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
OASMIA PHARMACEUTICAL AB (PUBL)-42.45%124
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640